Our Executive Team
-
Mitch SingerCEO
-
Evan SingerPresident
-
Linda SingerExecutive VP Creative Services
-
Adam SingerChief Expansion & Logistics Officer
-
Thomas CroweChief Supply Chain Officer
-
Dana S. ToopsChief Scientific Officer
-
Charles CainGeneral Counsel and CAO
-
Mitchell SladeCOO, PL Developments | President, PLD Gummy Co.
-
Tom CotterExecutive VP Business Development
-
Eddie GrimmVP Operations
-
Sophia SutphenVP Human Resources
-
Asaph NaamanChief Financial Officer
-
Anthony BartolomeoVP Creative Services
-
Yevgeniy YereshchenkoVP Information Technology
-
Patrick HeelanVP Logistics
-
Troy GamsChief Commercial Officer
-
Julie SolisVP of Pharmaceutical Technology
-
Joe CatalanoVP of Digital Transformation
-
Adam GraffVP of Finance
-
Suresh SanthanamVP of Revenue
-
Ramon TorresVP of Quality
Mitch Singer
About Mitch
Evan Singer
About Evan
Evan holds a B.S. in Business Management from the Robert H. Smith School of Business at the University of Maryland, with a focus on Logistics, Transportation, and Supply Chain Management. His academic background laid a solid foundation for his leadership in complex logistical operations and his ability to navigate the fast-evolving landscape of consumer healthcare.
Beyond his responsibilities as President, Evan is a Board member at PLD as well as two technology based start-up businesses, bringing his strategic insights and industry expertise to emerging technologies. He is also a member of the Young Presidents’ Organization (YPO), where he actively engages with a global network of leaders to share best practices and drive innovation.
Linda Singer
About Linda
Adam Singer
About Adam
Thomas Crowe
About Thomas
Dana S. Toops
About Dana
Dana has strong working knowledge of US FDA and GXPs, including participation in Type B and C FDA meetings, and two NDAs managed from submission through approval, including one REMS negotiation with the FDA. He has also been successful with more than fifteen ANDA submissions through the review and approval process with several pending applications under review. He has pharmacovigilance experience and has managed both nonclinical and clinical projects. He is currently an active member of the Regulatory Affairs Professional Society, the American Association of Pharmaceutical Scientists and a participant in the Association of Available Medicine.